These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 17523417)

  • 1. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 4. Harmonisation in pharmacovigilance.
    Edwards IR; Biriell C
    Drug Saf; 1994 Feb; 10(2):93-102. PubMed ID: 8011183
    [No Abstract]   [Full Text] [Related]  

  • 5. Wonder vigilance.
    Edwards IR
    Drug Saf; 2010 Feb; 33(2):83-6. PubMed ID: 20088622
    [No Abstract]   [Full Text] [Related]  

  • 6. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 7. [Methods for drug safety monitoring: yesterday, today, tomorrow].
    Nazimkin KE; Ovchinnikova EA; Zhuravleva MV
    Antibiot Khimioter; 2007; 52(7-8):41-52. PubMed ID: 18986024
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.
    Atuah KN; Hughes D; Pirmohamed M
    Drug Saf; 2004; 27(8):535-54. PubMed ID: 15154826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 10. Better reporting of adverse drug reactions.
    Abrutyn E
    Ann Intern Med; 1985 Feb; 102(2):264-5. PubMed ID: 3966766
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring drug product quality.
    Bolger G; Goetsch R; Reinstein P
    Am Pharm; 1992 Feb; NS32(2):47-9. PubMed ID: 1546630
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poisons centres and the reporting of adverse drug events: the case for further development.
    Volans GN; Karalliedde L; Wiseman HM
    Drug Saf; 2007; 30(3):191-4. PubMed ID: 17343427
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinicians' guide to adverse drug reactions.
    Ranganathan SS; Fernandopulle R
    Ceylon Med J; 2007 Jun; 52(2):41-4. PubMed ID: 17691557
    [No Abstract]   [Full Text] [Related]  

  • 20. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.